What to Watch When Johnson & Johnson Reports Tomorrow

Health and Healthcare

Published: July 15, 2019 12:55 pm

Last Updated: January 30, 2020 6:36 pm

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.43 in earnings per share (EPS) and $20.29 billion in revenue. The second quarter of last year reportedly had $2.10 in EPS and $20.83 billion in revenue.

In the first quarter, consumer worldwide operational sales were driven by over-the-counter products (including Tylenol analgesics, digestive health products and international anti-smoking aids) and Neutrogena beauty products, primarily offset by lower sales of baby care products. Overall consumer sales decreased 2.4% to $3.32 billion year over year.

Worldwide Medical Devices operational sales were driven by the growth of electrophysiology products in the Interventional Solutions business, Acuvue contact lenses in the Vision business, biosurgicals in the Advanced Surgery business and wound closure products in the General Surgery business. At that time, Medical Devices sales decreased 4.6% to $6.46 billion.

Finally, pharmaceutical worldwide operational sales were driven by a number of biologics and biosimilars including Stelara, Imbruvica, Darzalex, Tremfya, Erleada, Remicade and Zytiga to name a few. First-quarter pharmaceuticals sales increased 4.1% to $10.24 billion.

Excluding Monday’s move, Johnson & Johnson had underperformed the broad markets, with its stock down 4% year to date. In the past 52 weeks, the stock was up closer to 6%.

A few analysts weighed in on the firm ahead of the report:

Credit Suisse has an Outperform rating and a $156 price target.
Barclays has a Hold rating with a $140 price target.
Goldman Sachs has a Buy rating.
Wells Fargo’s Outperform rating comes with a $157 price target.
BMO Capital Markets has an Outperform rating and a $157 target.

Shares of Johnson & Johnson traded up 0.5% at $135.01 on Monday, in a 52-week range of $121.00 to $148.99. The consensus price target is $149.17.

24/7 Wall St.
Merrill Lynch’s Top Second-Half 2019 Small and Midcap Stock Picks

In 20 Years, I Haven’t Seen A Cash Back Card This Good

Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. Our top pick today has pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.